UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab Doesn't Need To Be Forgotten
September 17, 2014 at 09:50 AM EDT
In a report published Wednesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen, Inc. (NASDAQ: AMGN), ...